ScripsAmerica records $2.23 million in approved orders for May and June
"Recent changes in insurance coverage and nationwide policies have attributed to a decrease in volume for the specialty pharmacy industry as a whole which has impacted our sales," Brian Ettinger, interim CEO of ScripsAmerica, said. "As a result, management has been working diligently to expand our product and service offerings, distribution network and revenue stream in this market. ScripsAmerica has simultaneously continued to add clients and revenue in our diabetic, dispensing and wholesale divisions, which we believe will steadily contribute to an increase in shareholder value."
ScripsAmerica Inc. supplies prescription, OTC and nutraceutical drugs, retail pharmacies, hospitals, long-term care facilities and government and home care agencies.
"Additionally, we would like to inform our shareholders that the company holds the filing of its 2014 annual report and subsequent 2015 financials as its top priority," Ettinger said. "ScripsAmerica has also maintained its shares authorized and outstanding at approximately 140 million as we believe in forming a strong foundation from which we can grow by preventing any potential stock dilution moving forward."